Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rhea's Factory is a private Berkeley, California-based biotechnology company developing AI-designed enzymes and integrated biocatalytic processes to recycle contaminated plastic and textile waste into virgin-quality molecular building blocks. The company focuses on enzymatic depolymerization of difficult plastic streams, including polyester and mixed or layered materials, using proprietary enzyme blends, machine-learning-guided design, and process engineering. Its platform aims to enable circular manufacturing by converting waste into monomers that can be fed back into new production. Rhea's Factory appears to be an early-stage industrial biotech company rather than a healthcare or therapeutics developer. As of 2026, it remains privately held and has been publicly recognized through accelerators and innovation awards, including the 2026 Global Change Award.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rhea's Factory.